Jefferson City Headlines

Mesothelioma Pipeline

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Mesothelioma pipeline constitutes 45+ key companies continuously working towards developing 50+ Mesothelioma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Mesothelioma Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mesothelioma Market.

The Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ Mesothelioma Pipeline Outlook

Some of the key takeaways from the Mesothelioma Pipeline Report:

• Mesothelioma Companies across the globe are diligently working toward developing novel Mesothelioma treatment therapies with a considerable amount of success over the years. 
• Mesothelioma companies working in the treatment market are UTC Therapeutics, Molecular Templates, Biotheus, AstraZeneca, Adaptimmune, Astex Pharmaceuticals, Actym Therapeutics, A&G Pharmaceutical, Multitude Therapeutics, Constellation Pharmaceuticals, Checkpoint Therapeutics, Novartis Pharmaceuticals, Ikena Oncology and others, are developing therapies for the Mesothelioma treatment 
• Emerging Mesothelioma therapies such as Volrustomig, PM8002, MT-8421, and others are expected to have a significant impact on the Mesothelioma market in the coming years.   
• In March 2024, Verismo Therapeutics announced that it has activated a second clinical site for its STAR-101 Phase I clinical trial at The University of Texas MD Anderson Cancer Center for the treatment of malignant pleural mesothelioma.
• In February 2024, RS Oncology announced the successful dosing of the first patient in the Phase II dose expansion portion of its United Kingdom multicenter study (MITOPE; NCT05278975) for the treatment of malignant pleural mesothelioma.
• In December 2023, Sellas Life Sciences, had confirmed that its Phase I study (NCT02737787) of galinpepimut-S Combined with Opdivo (nivolumab) had hit its primary endpoint seeing increased overall survival in mesothelioma patients.
• In November 2023, AstraZeneca initiated a Phase III, randomized, open-label, multicenter, global study of Volrustomig (MEDI5752) in combination with Carboplatin plus Pemetrexed versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso). This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator’s choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma. The trial is currently recruiting the participants and is expected to be completed by March 2027, with an estimated enrollment of 600 participants.

Mesothelioma Overview

Mesothelioma is a rare and aggressive cancer that primarily affects the lining of the lungs (pleural mesothelioma) but can also occur in the lining of the abdomen (peritoneal mesothelioma), heart (pericardial mesothelioma), or testicles (testicular mesothelioma). The primary cause of mesothelioma is exposure to asbestos fibers, typically in occupational settings such as construction, mining, shipbuilding, and manufacturing.

Symptoms of mesothelioma often do not manifest until decades after exposure, complicating early diagnosis and treatment. Common symptoms include chest pain, shortness of breath, abdominal swelling, and unexplained weight loss. Diagnosis involves imaging tests such as X-rays, CT scans, and MRIs, followed by biopsy for confirmation.

Treatment options depend on the stage and location of the cancer but may include surgery, chemotherapy, radiation therapy, and emerging therapies such as immunotherapy and targeted therapy. Prognosis varies widely depending on factors like stage at diagnosis, overall health, and response to treatment. Despite advancements in treatment, mesothelioma remains challenging to cure due to its aggressive nature and late detection in many cases. Research continues to focus on improving early detection methods and developing more effective therapies to prolong survival and enhance quality of life for mesothelioma patients.

Get a Free Sample PDF Report to know more about Mesothelioma Pipeline Therapeutic Assessment- Mesothelioma Treatment Market

Mesothelioma Route of Administration

Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Mesothelioma Molecule Type

Mesothelioma Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Mesothelioma Pipeline Therapeutics Assessment

• Mesothelioma Assessment by Product Type
• Mesothelioma By Stage and Product Type
• Mesothelioma Assessment by Route of Administration
• Mesothelioma By Stage and Route of Administration
• Mesothelioma Assessment by Molecule Type
• Mesothelioma by Stage and Molecule Type

DelveInsight’s Mesothelioma Pipeline Report covers around 50+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Mesothelioma product details are provided in the report. Download the Mesothelioma pipeline report to learn more about the emerging Mesothelioma therapies- Mesothelioma Therapeutic Assessment

Mesothelioma Pipeline Analysis:

The Mesothelioma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Mesothelioma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mesothelioma Treatment.
• Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mesothelioma market.

Download Sample PDF Report to know more about Mesothelioma drugs and therapies – Mesothelioma Clinical Trials and FDA Approvals

Scope of Mesothelioma Pipeline Drug Insight    

• Coverage: Global
• Key Mesothelioma Companies: Afimmune, MediciNova, Mariposa Health Limited, MedWell Laboratories, BioElectron Technology, CSPC Ouyi Pharmaceutical, Veralox Therapeutics, Qurient Therapeutics, PTC Therapeutics and others.
• Key Mesothelioma Therapies: Epeleuton, Tipelukast, TA 270, MW 001, PTC 857, Baicalein, VLX 1005, Research programme: 5-Mesothelioma Inhibitor (LOX Inhibitor), and others.
• Mesothelioma Therapeutic Assessment: Mesothelioma current marketed and Mesothelioma emerging therapies
• Mesothelioma Market Dynamics: Mesothelioma market drivers and Mesothelioma market barriers 

Request for Sample PDF Report for Mesothelioma Pipeline Assessment and clinical trials – Mesothelioma Drugs and Therapies

Table of Contents

1. Mesothelioma Report Introduction

2. Mesothelioma Executive Summary

3. Mesothelioma Overview                

4. Mesothelioma- Analytical Perspective In-depth Commercial Assessment

5. Mesothelioma Pipeline Therapeutics

6. Mesothelioma Late Stage Products (Phase II/III)

7. Mesothelioma Mid Stage Products (Phase II)

8. Mesothelioma Early Stage Products (Phase I)

9. Mesothelioma Preclinical Stage Products

10. Mesothelioma Therapeutics Assessment

11. Mesothelioma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Mesothelioma Companies

14. Mesothelioma Key Products

15. Mesothelioma Unmet Needs

16 . Mesothelioma Market Drivers and Barriers

17. Mesothelioma Future Perspectives and Conclusion

18. Mesothelioma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting